- Earlier in May 2026, BeOne Medicines received U.S. FDA accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor.
- This first U.S. approval for sonrotoclax reshapes BeOne’s oncology profile by adding a new commercial pillar alongside its BTK franchise and broad late-stage pipeline.
- We’ll now examine how adding BEQALZI as an approved BCL2 inhibitor could reshape BeOne Medicines’ investment narrative and future oncology positioning.
Find 49 companies with promising cash flow potential yet trading below their fair value.
BeOne Medicines Investment Narrative Recap
To own BeOne Medicines, you need to believe it can turn its hematology strength into a multi‑pillar oncology business while managing heavy reliance on BRUKINSA and rising R&D spend. The accelerated approval of BEQALZI adds a second U.S. commercial anchor and could ease single‑product risk, but the key near‑term catalyst remains execution on late‑stage trials across BTK, BCL2 and solid tumors, while the biggest risk is still pricing and competitive pressure on the CLL/BTK franchise.
The BEQALZI approval is especially relevant when viewed alongside BeOne’s raised 2026 revenue guidance to US$6.3–US$6.5 billion and its strong Q1 2026 results, which showed net product revenue of US$1.487 billion and improving margins. Together, they highlight how quickly sonrotoclax is moving from pipeline asset to commercial pillar, potentially reshaping expectations around future hematology readouts and regulatory milestones that investors are watching most closely.
Yet, against this momentum, investors should be aware that concentration in BRUKINSA‑driven CLL revenue still leaves BeOne exposed if...
Read the full narrative on BeOne Medicines (it's free!)
BeOne Medicines' narrative projects $8.6 billion revenue and $1.6 billion earnings by 2029. This requires 14.3% yearly revenue growth and an earnings increase of about $1.1 billion from $513.0 million today.
Uncover how BeOne Medicines' forecasts yield a $411.51 fair value, a 33% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming BeOne could reach about US$9.5 billion of revenue and US$2.1 billion of earnings by 2029, but the BEQALZI news could either reinforce that bullish view on hematology leadership or challenge it if you worry more about BRUKINSA concentration and pricing risk, so it is worth comparing these more aggressive assumptions with your own expectations.
Explore 5 other fair value estimates on BeOne Medicines - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.
Ready For A Different Approach?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com